OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees

OA04-02. Strong HIV-specific CD4 and CD8 T-lymphocyte proliferation in HIV-1 DNA prime/modified vaccinia virus Ankara (MVA) heterologous boost vaccinees

Bibliographic Details
Main Authors:	Biberfeld G, Sandström E, Gaines H, Marovich M, Wahren B, Karlén K, Aboud S, Nilsson C, Godoy-Ramirez K
Format:	Article
Language:	English
Published:	BMC 2009-10-01
Series:	Retrovirology

Similar Items

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults
by: Joachim A, et al.
Published: (2012-09-01)

HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
by: Charlotta Nilsson, et al.
Published: (2015-01-01)

Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.
by: Agricola Joachim, et al.
Published: (2015-01-01)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
by: Bauer A, et al.
Published: (2012-09-01)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
by: Jeffrey R Currier, et al.
Published: (2010-11-01)

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine
by: Munseri P, et al.
Published: (2012-09-01)

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
by: Maria L Knudsen, et al.
Published: (2015-01-01)

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA
by: Wahren B, et al.
Published: (2009-10-01)

Diseño y construcción de vectores de transferencia para la obtención de virus vaccinia Ankara modificado (MVA) recombinantes Design and construction of transfer vectors in order to obtain recombinant modified vaccinia virus Ankara (MVA)
by: M. F. Ferrer, et al.
Published: (2007-09-01)

Characterisation of CD8+T cell responses induced by therapeutic vaccination with HIV-1 clade A gag DNA- and recombinant modified vaccinia virus Ankara (MVA)-vectored vaccines in HIV-1 infected individuals recieving highly active antiretroviaral therapy
by: Yang, Hongbing
Published: (2007)

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
by: Podola L, et al.
Published: (2012-09-01)

A Genotype of Modified Vaccinia Ankara (MVA) that Facilitates Replication in Suspension Cultures in Chemically Defined Medium
by: Volker Sandig, et al.
Published: (2013-01-01)

OA031-04. Impairment of HIV-1-specific CD8+ T cell function by soluble epithelial adhesion molecules
by: Rodig SJ, et al.
Published: (2009-10-01)

Untersuchung von Modifiziertem Vaccinia Ankara Virus (MVA) zur Induktion Cytomegalovirus (CMV) spezifischer T-Zell-Antworten
by: Flechsig, Christin
Published: (2011)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Matthew G Cottingham, et al.
Published: (2008-02-01)

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases
by: Arwen F. Altenburg, et al.
Published: (2014-07-01)

Caracterização da resposta imune induzida pelo vírus Vaccinia Ankara modificado (MVA) em modelo murino
by: Lorena Falabella Daher de Freitas
Published: (2011)

Frequent and Durable Anti-HIV Envelope VIV2 IgG Responses Induced by HIV-1 DNA Priming and HIV-MVA Boosting in Healthy Tanzanian Volunteers
by: Agricola Joachim, et al.
Published: (2020-11-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
by: Matthew G. Cottingham, et al.
Published: (2011-01-01)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
by: Maurilia Marcacci, et al.
Published: (2020-07-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
by: Matthew G. Cottingham, et al.
Published: (2011-01-01)

Studies of heterologous regimens for HIV-1 vaccines by rBCG and rMVA vectors
by: Hopkins, Richard
Published: (2010)

A Systematic, Unbiased Mapping of CD8+ and CD4+ T Cell Epitopes in Yellow Fever Vaccinees
by: Anette Stryhn, et al.
Published: (2020-08-01)

OA02-06 LB. Recombinant modified Vaccinia virus ankara expressing HIV-1 genes activates NK subset capable of controlling HIN infection in vitro
by: Barré-Sinoussi F, et al.
Published: (2009-10-01)

A Soluble Version of Nipah Virus Glycoprotein G Delivered by Vaccinia Virus MVA Activates Specific CD8 and CD4 T Cells in Mice
by: Georgia Kalodimou, et al.
Published: (2019-12-01)

Zinc-finger antiviral protein (ZAP) is a restriction factor for replication of modified vaccinia virus Ankara (MVA) in human cells.
by: Chen Peng, et al.
Published: (2020-08-01)

Induction of antibody responses to African horse sickness virus (AHSV) in ponies after vaccination with recombinant modified vaccinia Ankara (MVA).
by: Rachael Chiam, et al.
Published: (2009-06-01)

CD8+ T Cells Responding to the Middle East Respiratory Syndrome Coronavirus Nucleocapsid Protein Delivered by Vaccinia Virus MVA in Mice
by: Svenja Veit, et al.
Published: (2018-12-01)

0A07-01. HIV-specific CD8<sup>+ </sup>T-cells of vaccinees exhibit proliferative and cytotoxic capacities comparable to those of progressors
by: McElrath J, et al.
Published: (2009-10-01)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
by: Patricia Pérez, et al.
Published: (2020-02-01)

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome.
by: Julie Delaloye, et al.
Published: (2009-06-01)

SPI-1 is a missing host-range factor required for replication of the attenuated modified vaccinia Ankara (MVA) vaccine vector in human cells.
by: Ruikang Liu, et al.
Published: (2019-05-01)

Induction of Identical IgG HIV-1 Envelope Epitope Recognition Patterns After Initial HIVIS-DNA/MVA-CMDR Immunization and a Late MVA-CMDR Boost
by: Agricola Joachim, et al.
Published: (2020-04-01)

Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals
by: Adrien Leite Pereira, et al.
Published: (2020-09-01)

OA06-04. The role of early T-cell responses in subjects with acute HIV-1 infection
by: Hahn B, et al.
Published: (2009-10-01)

Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression
by: Joana Vitallé, et al.
Published: (2017-07-01)

DNA/MVA Vaccines for HIV/AIDS
by: Smita S. Iyer, et al.
Published: (2014-02-01)

Neutrophil subtypes shape HIV-specific CD8 T-cell responses after vaccinia virus infection
by: Mauro Di Pilato, et al.
Published: (2021-04-01)

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
by: Juan García-Arriaza, et al.
Published: (2011-01-01)

OA031-02. Regulatory T cells inhibit CD8 T cell proliferation in HIV-1 infection through CD39/adenosine pathway
by: Lévy Y, et al.
Published: (2009-10-01)